Nicolette Stogios

Dr. Nicolette Stogios

University of Toronto - Institute of Medical Science
+1
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2021 in Schizophrenia
Verified
Journal Article
Open access
PDF file
NSNicolette Stogios
Nicolette Stogios
AGAlexander Gdanski
Alexander Gdanski
PGPhilip Gerretsen
Philip Gerretsen
ACAraba F. Chintoh
Araba F. Chintoh
AGAriel Graff-Guerrero
Ariel Graff-Guerrero
SASri Mahavir Agarwal
Sri Mahavir Agarwal
Schizophrenia (SCZ) is a psychiatric disorder characterized by a wide range of positive, negative and cognitive symptoms, along with an increased risk of metabolic syndrome and cardiovascular disease that contribute to a 15–20-year reduced life expectancy. Autonomic dysfunction, in the form of increased sympathetic activity and decreased parasympathetic activity, is postulated to be implicated in SCZ and its treatment. The aim of this narrative review is to view SCZ through an autonomic lens and synthesize the evidence relating autonomic dysfunction to different domains of SCZ. Using various methods of assessing autonomic activity, autonomic dysfunction was found to be associated with multiple aspects of SCZ pathophysiology, including symptom severity, cognitive impairment, and the development of cardiometabolic comorbidities, such as metabolic syndrome and high BMI. The strongest association of low heart rate variability was noted among patients on antipsychotic treatment with high-affinity muscarinic antagonism (i.e., clozapine, olanzapine and quetiapine). The review will also suggest ways in which studying autonomic dysfunction can help reduce morbidity and mortality associated with SCZ and its treatment.

2 December 2019 in Expert Opinion on Drug Safety
Verified
Journal Article
Closed access
KCKenya A. Costa-Dookhan
Kenya A. Costa-Dookhan
SASri Mahavir Agarwal
Sri Mahavir Agarwal
ACAraba Chintoh
Araba Chintoh
VTVeronica N. Tran
Veronica N. Tran
NSNicolette Stogios
Nicolette Stogios
Margaret HahnMargaret Hahn
Margaret Hahn
Introduction: Clozapine remains the most effective antipsychotic for treatment refractory schizophrenia. However, ~40% of patients respond insufficiently to clozapine. Clozapine’s effects, both beneficial and adverse, have been proposed to be partially attributable to its main metabolite, N-desmethylclozapine (NDMC). However, the relation of the clozapine to norclozapine ratio (CLZ:NDMC; optimally defined as ~2) to clinical response and metabolic outcomes is not clear. Areas covered: This narrative review comprehensively examines the clinical utility of the CLZ:NDMC ratio to reduce metabolic risk and increase treatment efficacy. The association of the CLZ:NDMC ratio with changes in psychopathology, cognitive functioning, and cardiometabolic burden will be explored, as well as adjunctive treatments and their effects. Expert opinion: The literature suggests a positive association between the CLZ:NDMC ratio and better cardiometabolic outcomes. Conversely, the CLZ:NDMC ratio appears inversely associated with better cognitive functioning but less consistently with other psychiatric domains. The CLZ:NDMC ratio may be useful for predicting and monitoring cardiometabolic adverse effects and optimizing potential cognitive benefits of clozapine. Future studies are required to replicate these findings, which if substantiated, would encourage examination of adjunctive treatments aiming to alter the CLZ:NDMC ratio to best meet the needs of the individual patient, thereby broadening clozapine’s clinical utility.

18 December 2020 in Nutrients
Verified
Journal Article
Open access
PDF file
NSNicolette Stogios
Nicolette Stogios
Emily SmithEmily Smith
Emily Smith
RARoshanak Asgariroozbehani
Roshanak Asgariroozbehani
LHLaurie Hamel
Laurie Hamel
AGAlexander Gdanski
Alexander Gdanski
Margaret HahnMargaret Hahn
Margaret Hahn
Disturbed eating behaviours have been widely reported in psychotic disorders since the early 19th century. There is also evidence that antipsychotic (AP) treatment may induce binge eating or other related compulsive eating behaviours. It is therefore possible that abnormal eating patterns may contribute to the significant weight gain and other metabolic disturbances observed in patients with psychosis. In this scoping review, we aimed to explore the underlying psychopathological and neurobiological mechanisms of disrupted eating behaviours in psychosis spectrum disorders and the role of APs in this relationship. A systematic search identified 35 studies that met our eligibility criteria and were included in our qualitative synthesis. Synthesizing evidence from self-report questionnaires and food surveys, we found that patients with psychosis exhibit increased appetite and craving for fatty food, as well as increased caloric intake and snacking, which may be associated with increased disinhibition. Limited evidence from neuroimaging studies suggested that AP-naïve first episode patients exhibit similar neural processing of food to healthy controls, while chronic AP exposure may lead to decreased activity in satiety areas and increased activity in areas associated with reward anticipation. Overall, this review supports the notion that AP use can lead to disturbed eating patterns in patients, which may contribute to AP-induced weight gain. However, intrinsic illness-related effects on eating behaviors remain less well elucidated, and many confounding factors as well as variability in study designs limits interpretation of existing literature in this field and precludes firm conclusions from being made.

1 May 2020 in Canadian Journal of Cardiology
Verified
Journal Article
Open access
NSNicolette Stogios
Nicolette Stogios
BKBhagwanpreet Kaur
Bhagwanpreet Kaur
EHElla Huszti
Ella Huszti
JVJessica Vasanthan
Jessica Vasanthan
RNRobert P. Nolan
Robert P. Nolan
Behavioural counselling via internet- or mobile-based digital platforms is recommended for hypertension; however, outcome heterogeneity is problematic in trials of this digital intervention. Our objective was to assess how therapeutic outcome was optimized in digital trials for hypertension, according to key features of the intervention design and protocol. We identified randomized controlled digital trials for systolic blood pressure (SBP) reduction in taskforce guideline and policy statements, systematic reviews, and meta-analyses published since 2010, by searching the EMBASE, Cochrane Library, psycINFO, and PubMed databases. This search was updated to January 2019. Trials included patients with elevated cardiovascular risk or cardiovascular disease. We classified digital trials by the number of components of the intervention, and whether the protocol was organized by an explicit model of behavioural change or counselling. The influence of these features was evaluated for treatment efficacy and heterogeneity of SBP outcomes. Seventeen trials met inclusion criteria: pooled n = 5780, 33% female, 93% taking antihypertensive medications. SBP reduction was -7.3 mm Hg for digital counselling (95% confidence interval: -7.0 to -7.5) vs -3.6 mm Hg for control (95% confidence interval: -3.4 to -3.9), P < 0.0001, with high-moderate heterogeneity (I2 = 67%). Trials with multiple behavioural intervention components and an organized theoretical framework of behaviour change or counselling demonstrated optimal SBP reduction with low-moderate heterogeneity (I2 = 49%). Digital health interventions optimize the efficacy of medical therapy for SBP reduction. There is opportunity to promote a disruptive change in clinical science that accompanies technological developments in digital health promotion.

1 April 2023 in Schizophrenia Bulletin
Verified
Journal Article
Closed access
PDF file
SASri Mahavir Agarwal
Sri Mahavir Agarwal
NSNicolette Stogios
Nicolette Stogios
GFGuy E J Faulkner
Guy E J Faulkner
Margaret HahnMargaret Hahn
Margaret Hahn
Patients with schizophrenia are burdened by higher rates of obesity, cardiovascular disease and reduced life expectancy than the general population. In addition to illness, genetic and lifestyle factors, the associated weight gain and metabolic adverse effects of antipsychotic (AP) medications are known to exacerbate and accelerate these cardiometabolic problems significantly. Given the detrimental consequences of weight gain and other metabolic disturbances, there is an urgent need for safe and effective strategies to manage these issues as early on as possible. This review summarizes the literature of adjunctive pharmacological interventions aimed at preventing AP-induced weight gain.

11 September 2023 in Expert Opinion on Pharmacotherapy
Verified
Journal Article
Closed access
RDRiddhita De
Riddhita De
FPFemin Prasad
Femin Prasad
NSNicolette Stogios
Nicolette Stogios
LBLuisa Burin
Luisa Burin
BEBjørn H. Ebdrup
Bjørn H. Ebdrup
SASri Mahavir Agarwal
Sri Mahavir Agarwal
IntroductionPsychotropic medications, especially antipsychotics, have been consistently shown to cause weight gain in individuals with severe mental illness (SMI), a population inherently challenged by poor physical health. Consequently, compared to the general population, this contributes to an increased cardiometabolic burden, including the risk of type 2 diabetes, dyslipidemia, and hypertension. Furthermore, comorbid obesity leads to treatment nonadherence, decreased quality of life, and increased risk of relapse, posing a challenge in the management of mental health. To address this, emerging agents investigated in the general population with potential to mitigate weight gain were explored to assess translatability to the SMI population.Areas coveredA literature search was conducted including agents approved for the management of obesity in the general population, along with upcoming agents under investigation in phase III trials with weight loss properties.Expert opinionMetformin and topiramate along with lifestyle interventions are commonly prescribed for weight gain in individuals with SMI; however, their weight loss potential is modest at best. This review identified tirzepatide and cagrilintide-semaglutide among others as promising agents for adjunctive pharmacological management of weight gain.